XBIT - エックスバイオテック （XBiotech Inc.）XBITのニュース
Let’s Talk About How XBiotech Inc. (NASDAQ: XBIT) Stock Is Doing. 2022/06/20 19:00:00 Marketing Sentinel
In the last trading session, 0.21 million shares of the XBiotech Inc. (NASDAQ:XBIT) were traded, and its beta was 1.41. Most recently the company’s share price was $5.13, and it changed around -$0.13 or -2.47% from the last close, which brings the market valuation of the company to $161.95M. XBIT currently trades at a discount … Let’s Talk About How XBiotech Inc. (NASDAQ: XBIT) Stock Is Doing. Read More »
XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study 2022/06/20 13:00:00 GlobeNewswire
Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic Cancer Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic Cancer
Why Are XBiotech Shares Trading Higher Today 2022/04/28 18:53:21 Benzinga
The French authority has signed off XBiotech Inc''s (NASDAQ: XBIT ) multicenter randomized clinical study for Natrunix combined with trifluridine/tipiracil for colorectal cancer. The French National Cancer Institute (INCA) has also awarded a grant to fund all clinical costs for the study. Investigators will combine Natrunix and trifluridine/tipiracil as a new candidate therapy for metastatic colorectal cancer … Full story available on Benzinga.com
XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer 2022/04/28 13:00:00 Wallstreet:Online
ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in France AUSTIN, Texas, April 28, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that the French National Agency for the Safety of Medicines and Health Products [L''Agence nationale de sécurité du médicament et des produits de santé (ANSM)] approved the launch of a multicenter randomized
XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer 2022/04/28 13:00:00 GlobeNewswire
ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in France ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in France
Wells Fargo & Company MN Sells 17,033 Shares of XBiotech Inc. (NASDAQ:XBIT) 2021/12/12 09:38:42 Transcript Daily
Wells Fargo & Company MN reduced its stake in XBiotech Inc. (NASDAQ:XBIT) by 7.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 210,484 shares of the biopharmaceutical companys stock after selling 17,033 shares during the period. Wells Fargo & Company []
XBiotech Inc.: XBiotech to Launch Novel Candidate Therapy for Stroke 2021/10/28 16:05:00 FinanzNachrichten
Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After StrokeAUSTIN, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT)
XBiotech to Launch Novel Candidate Therapy for Stroke 2021/10/28 15:59:00 Intrado Digital Media
Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke
Citigroup Inc. Has $48,000 Holdings in XBiotech Inc. (NASDAQ:XBIT) 2021/10/23 08:20:41 Transcript Daily
Citigroup Inc. grew its position in XBiotech Inc. (NASDAQ:XBIT) by 72.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,881 shares of the biopharmaceutical companys stock after purchasing an additional 1,211 shares during the period. Citigroup Inc.s holdings in XBiotech []
Xbiotech Inc (XBIT) CEO John Simard Sold $1.1 million of Shares 2021/10/16 01:15:01 GuruFocus
Related Stocks: XBIT ,
XBiotech Inc.: XBiotech to Launch Novel Candidate Therapy for Stroke 2021/10/28 16:05:00 FinanzNachrichten
Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After StrokeAUSTIN, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT)
XBiotech to Launch Novel Candidate Therapy for Stroke 2021/10/28 15:59:00 Intrado Digital Media
Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke
Citigroup Inc. Has $48,000 Holdings in XBiotech Inc. (NASDAQ:XBIT) 2021/10/23 08:20:41 Transcript Daily
Citigroup Inc. grew its position in XBiotech Inc. (NASDAQ:XBIT) by 72.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,881 shares of the biopharmaceutical companys stock after purchasing an additional 1,211 shares during the period. Citigroup Inc.s holdings in XBiotech []